2 min read
A clinical trial rocked the cardiology community this week — not for what it showed, but for what it didn’t. On September 4, Novartis announced that pelacarsen, a drug targeting the cholesterol particle known as lipoprotein(a), or Lp(a), failed to significantly reduce the risk of cardiovascular death, heart attack, or stroke. One of the most anticipated drugs in cardiology turned out to be a dud.
Just this year, new cholesterol guidelines from the American Heart Association and American College of Cardiology recommended that all adults get their lipoprotein(a) checked at least once in their lifetime. The reason? Decades of research…
Read the full article at MENSHEALTH.COM
